TIMOTHY KANE: Open Payments
NPI 1205805355 · STAUNTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$101,937 in 277 payments from 16 companies in 2025. Trend: 2023 $17,619 · 2024 $25,853 · 2025 $101,937
Speaker / faculty: $76,975Honoraria: $9,213Consulting: $6,938Food & beverage: $4,840Travel & lodging: $3,749Education: $223
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 111 | $69,870 |
| ABBVIE INC. | 53 | $20,372 |
| Axsome Therapeutics, Inc. | 10 | $9,715 |
| Teva Pharmaceuticals USA, Inc. | 12 | $342 |
| Janssen Pharmaceuticals, Inc | 10 | $264 |
| Neurocrine BioSciences, Inc. | 18 | $264 |
| Vanda Pharmaceuticals Inc. | 11 | $261 |
| Otsuka America Pharmaceutical, Inc. | 15 | $224 |
| Alkermes, Inc. | 15 | $185 |
| E.R. Squibb & Sons, L.L.C. | 7 | $143 |
Products named: CAPLYTA, VRAYLAR, Auvelity, INGREZZA, REXULTI, FANAPT, INVEGA SUSTENNA, ARISTADA.
Industry payments across VA — which companies pay providers there.
